Hepatitis C Elimination Works: Ten Years of Evidence from Seven Countries
A new report marks ten years of CHAI-supported hepatitis C programs in Cambodia, India, Indonesia, Myanmar, Nigeria, Rwanda, and Vietnam. More
Calendar
Recent materials
TAG and LAT CAB Welcome Indian Patent Office Decision That Could Expand Access to Hepatitis C Treatment
TAG and the LAT CAB celebrate the Indian Patent Office’s decision to NOT grant a patent on the HCV combination treatment glecaprevir/pibrentasvir, aka Mavyret® or Maviret® manufactured by AbbVie. More
New Report Warns International Drug Policy Is Failing — as ‘War on Drugs’ Regains Momentum
As the United Nations embarks on far-reaching institutional reform, a major new report from the International Drug Policy Consortium delivers a stark warning: global drug control is failing. More
WHO Operational Guide: Needle and Syringe Programmes for People Who Inject Drugs
The document provides practical, evidence-based guidance to support countries in planning, implementing and scaling up needle and syringe programmes for people who inject drugs as part of comprehensive harm reduction responses. More
Voices From the Frontline: How Global Funding Cuts Are Reshaping the Viral Hepatitis Response
In a commentary, published in The Lancet Gastroenterology & Hepatology, frontline voices reveal how recent global health funding cuts are already disrupting hepatitis B and C services worldwide. More
C-Free Study: Integrated Model of Care in Curing Hepatitis C in People Who Use Drugs in Thailand
The C-Free study concludes that community-based HCV treatment of people who use drugs in Thailand, within harm reduction settings, is safe and effective. More
